Dutasteride 0.5 mg (DrugBank: Dutasteride)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
1 | Spinal and bulbar muscular atrophy | 0 |
2 | Amyotrophic lateral sclerosis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04654689 (ClinicalTrials.gov) | January 2021 | 13/11/2020 | Impact of the Combined Treatment of Liposomed Polyphenols With Dutasteride on the ALS Patients | Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With Dutasteride on the Clinical Improvement of ALS Patients | Amyotrophic Lateral Sclerosis | Dietary Supplement: Liposomed polyphenols resveratrol and curcumin;Other: Placebo for liposomed resveratrol and curcumin;Dietary Supplement: Isocaloric Diet;Drug: Dutasteride 0.5 mg;Other: Placebo microcrystalline methylcellulose | Fundación Universidad Católica de Valencia San Vicente Mártir | NULL | Not yet recruiting | 18 Years | 75 Years | All | 100 | Phase 2 | Spain |